EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

2012, EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016/j.jhep.2011.12.001

Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD

Akinyemiju, 2017, The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level, JAMA Oncol, 3, 1683, 10.1001/jamaoncol.2017.3055

El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061

White, 2017, Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012, Gastroenterology, 152, 812, 10.1053/j.gastro.2016.11.020

Tanaka, 2008, Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003, Ann Intern Med, 148, 820, 10.7326/0003-4819-148-11-200806030-00004

Qiu, 2009, A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958–2004), Int J Cancer, 124, 443, 10.1002/ijc.23911

Fact Sheets by Population-Globocan-IARC n.d. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed December 18, 2017)

Bosetti, 2008, Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004, Hepatology, 48, 137, 10.1002/hep.22312

Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073

Welzel, 2013, Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States, Am J Gastroenterol, 108, 1314, 10.1038/ajg.2013.160

El-Serag, 2014, Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?, Hepatology, 60, 1767, 10.1002/hep.27222

Chang, 2009, Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study, J Natl Cancer Inst, 101, 1348, 10.1093/jnci/djp288

Chang, 2016, Long-term effects of hepatitis B immunization of infants in preventing liver cancer, Gastroenterology, 21

Sangiovanni, 2006, The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients, Hepatology, 43, 1303, 10.1002/hep.21176

Ioannou, 2007, Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, 5, 938, 10.1016/j.cgh.2007.02.039

Lok, 2009, Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease, Gastroenterology, 136, 138, 10.1053/j.gastro.2008.09.014

Ripoll, 2009, Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis, J Hepatol, 50, 923, 10.1016/j.jhep.2009.01.014

Masuzaki, 2008, Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography, J Clin Gastroenterol, 42, 839, 10.1097/MCG.0b013e318050074f

Masuzaki, 2009, Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography, Hepatology, 49, 1954, 10.1002/hep.22870

Jung, 2011, Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan), Hepatology, 53, 885, 10.1002/hep.24121

Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:1573–84-2-9.

Wong GL-H, Chan HL-Y, Wong CK-Y, Leung C, Chan CY, Ho PP-L, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol 2014;60:339–45.

Kim, 2015, Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis, Hepatology, 61, 1851, 10.1002/hep.27735

Yang, 2002, Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Med, 347, 168, 10.1056/NEJMoa013215

Chen, 2006, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001/jama.295.1.65

Yu, 2005, Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men, J Natl Cancer Inst, 97, 265, 10.1093/jnci/dji043

Iloeje, 2006, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053/j.gastro.2005.11.016

Raimondi, 2009, Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis, J Hepatol, 50, 1142, 10.1016/j.jhep.2009.01.019

Kanwal, 2014, HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV, Hepatology, 60, 98, 10.1002/hep.27095

Hsu, 1991, Mutational hotspot in the p53 gene in human hepatocellular carcinomas, Nature, 350, 427, 10.1038/350427a0

Nahon, 2009, Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis, Hepatology, 50, 1484, 10.1002/hep.23187

Mancebo, 2012, Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups, Clin Gastroenterol Hepatol, 11, 95, 10.1016/j.cgh.2012.09.007

Deugnier, 1993, Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases, Gastroenterology, 104, 228, 10.1016/0016-5085(93)90856-8

Fracanzani, 2001, Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease, Hepatology, 33, 647, 10.1053/jhep.2001.22506

Andant, 2000, Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors, J Hepatol, 32, 933, 10.1016/S0168-8278(00)80097-5

Fracanzani, 2001, Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease, J Hepatol, 498, 10.1016/S0168-8278(01)00160-X

Perlmutter, 2006, Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency, Pediatr Res, 60, 233, 10.1203/01.pdr.0000228350.61496.90

Schlesinger, 2013, Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort, Ann Oncol, 24, 2449, 10.1093/annonc/mdt204

Tsilidis, 2015, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies, BMJ, 350, g7607, 10.1136/bmj.g7607

Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423

Chen, 2008, Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan, Gastroenterology, 135, 111, 10.1053/j.gastro.2008.03.073

Yu, 2017, Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study, Gastroenterology, 153, 1006, 10.1053/j.gastro.2017.07.001

Dyson, 2014, Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team, J Hepatol, 60, 110, 10.1016/j.jhep.2013.08.011

Kanwal F, Kramer JR, Duan Z, Yu X, White D, El-Serag HB. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol 2016;14:301-8-2.

Younossi, 2015, Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009, Hepatology, 62, 1723, 10.1002/hep.28123

Younossi, 2016, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 64, 1577, 10.1002/hep.28785

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388–402.

Degasperi, 2016, Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease, Lancet Gastroenterol Hepatol, 1, 156, 10.1016/S2468-1253(16)30018-8

Piscaglia, 2016, Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study, Hepatology, 63, 827, 10.1002/hep.28368

Marrero, 2005, Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma, J Hepatol, 42, 218, 10.1016/j.jhep.2004.10.005

Trichopoulos, 2011, Hepatocellular carcinoma risk factors and disease burden in a european cohort: a nested case-control study, JNCI J Natl Cancer Inst, 103, 1686, 10.1093/jnci/djr395

Ioannou, 2013, The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection, Hepatology, 57, 249, 10.1002/hep.25800

Weekly epidemiological record Relevé épidémiologique hebdomadaire 2017;92:369–92.

2017, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 2017, 370

2018, European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018, J Hepatol

Niederau, 1996, Long-term follow-up of HBeAg-positive patients treated with interferon Alfa for chronic hepatitis B, N Engl J Med, 334, 1422, 10.1056/NEJM199605303342202

Papatheodoridis, 2015, Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy, J Hepatol, 62, 956, 10.1016/j.jhep.2015.01.002

Varbobitis, 2016, The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy, Clin Mol Hepatol, 22, 319, 10.3350/cmh.2016.0045

Papatheodoridis, 2017, The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B, Hepatology, 66, 1444, 10.1002/hep.29320

Su, 2016, Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients, Liver Int, 36, 1755, 10.1111/liv.13253

van der Meer, 2012, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, 308, 2584, 10.1001/jama.2012.144878

Morgan, 2013, Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies, Ann Intern Med, 158, 329, 10.7326/0003-4819-158-5-201303050-00005

Colombo, 2014, Role of antiviral treatment for HCC prevention, Best Pract Res Clin Gastroenterol, 28, 771, 10.1016/j.bpg.2014.07.017

D’Ambrosio, 2015, Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy, Int J Mol Sci, 16, 19698, 10.3390/ijms160819698

2015, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, 62, 932, 10.1002/hep.27950

Reig, 2016, Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy, J Hepatol, 65, 719, 10.1016/j.jhep.2016.04.008

Conti, 2016, Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals, J Hepatol, 65, 727, 10.1016/j.jhep.2016.06.015

Romano A, Capra F, Piovesan S, Chemello L, Cavalletto L, Anastassopoulos G, et al. Incidence and pattern of “de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs. Hepatology 2016;64: Abstract 19.

Foster, 2016, Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 64, 1224, 10.1016/j.jhep.2016.01.029

Cheung, 2016, Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 65, 741, 10.1016/j.jhep.2016.06.019

2016, Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts, J Hepatol, 65, 734, 10.1016/j.jhep.2016.05.045

Sugimoto, 2015, Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma, Oncology, 89, 42, 10.1159/000440630

Kobayashi, 2017, Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection, J Med Virol, 89, 476, 10.1002/jmv.24663

Petta, 2017, Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon, Aliment Pharmacol Ther, 45, 160, 10.1111/apt.13821

Cabibbo, 2017, Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study, Aliment Pharmacol Ther, 46, 688, 10.1111/apt.14256

Waziry, 2017, Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression, J Hepatol, 67, 1204, 10.1016/j.jhep.2017.07.025

Kanwal, 2017, Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents, Gastroenterology, 153, 996, 10.1053/j.gastro.2017.06.012

Reig, 2017, Liver cancer emergence associated with antiviral treatment: an immune surveillance failure?, Semin Liver Dis, 37, 109, 10.1055/s-0037-1601349

Inoue, 2005, Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan, J Natl Cancer Inst, 97, 293, 10.1093/jnci/dji040

Gelatti, 2005, Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study, J Hepatol, 42, 528, 10.1016/j.jhep.2004.11.039

Bravi, 2007, Coffee drinking and hepatocellular carcinoma risk: A meta-analysis, Hepatology, 46, 430, 10.1002/hep.21708

Bravi, 2016, Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies, Eur J Cancer Prev

Aleksandrova, 2015, The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition, Am J Clin Nutr, 102, 1498, 10.3945/ajcn.115.116095

Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015;148:118–25; quiz e15.

Prorok, 1992, Epidemiologic approach for cancer screening. Problems in design and analysis of trials, Am J Pediatr Hematol Oncol, 14, 117, 10.1097/00043426-199205000-00005

Forner, 2018, Hepatocellular carcinoma, Lancet, 10.1016/S0140-6736(18)30010-2

Laupacis, 1992, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations, CMAJ, 146, 473

McCabe, 2008, The NICE cost-effectiveness threshold: what it is and what that means, Pharmacoeconomics, 26, 733, 10.2165/00019053-200826090-00004

Neumann, 2014, Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold, N Engl J Med, 371, 796, 10.1056/NEJMp1405158

Sarasin, 1996, Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis, Am J Med, 101, 422, 10.1016/S0002-9343(96)00197-0

Sherman, 2014, Surveillance for hepatocellular carcinoma, Best Pract Res Clin Gastroenterol, 28, 783, 10.1016/j.bpg.2014.08.008

Díaz-González, 2016, Surveillance for hepatocellular carcinoma, Best Pract Res Clin Gastroenterol, 30, 1001, 10.1016/j.bpg.2016.10.006

Trevisani, 2007, Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?, Am J Gastroenterol, 102, 2448, 10.1111/j.1572-0241.2007.01395.x

Sanchez-Tapias, 2002, Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients, Gastroenterology, 123, 1848, 10.1053/gast.2002.37041

Fattovich, 2008, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors, J Hepatol, 48, 335, 10.1016/j.jhep.2007.11.011

Chen, 2009, Hepatitis B virus DNA levels and outcomes in chronic hepatitis B, Hepatology, 49, S72, 10.1002/hep.22884

Yang, 2011, Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score, Lancet Oncol, 12, 568, 10.1016/S1470-2045(11)70077-8

Wong VW-S, Janssen HLA. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 2015;63:722–32.

Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002/hep.22734

Kolly, 2016, Surveillance for hepatocellular carcinoma in patients with NASH, Diagnostics, 6, 22, 10.3390/diagnostics6020022

Dongiovanni, 2014, Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors, World J Gastroenterol, 20, 12945, 10.3748/wjg.v20.i36.12945

Ajmera, 2017, Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review, Hepatology, 65, 2090, 10.1002/hep.29055

Burza, 2012, PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals, Dig Liver Dis, 44, 1037, 10.1016/j.dld.2012.05.006

Liu, 2014, Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma, J Hepatol, 61, 75, 10.1016/j.jhep.2014.02.030

Yasui, 2011, Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma, Clin Gastroenterol Hepatol, 9, 428, 10.1016/j.cgh.2011.01.023

Wong GL-H, Chan HL-Y, Chan H-Y, Tse PC-H, Tse Y-K, Mak CW-H, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013;144:933–44.

Sung, 2008, Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma, Aliment Pharmacol Ther, 28, 1067, 10.1111/j.1365-2036.2008.03816.x

Wang, 2016, Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy, Liver Int, 36, 1793, 10.1111/liv.13179

Wang, 2013, Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients, Liver Int, 33, 756, 10.1111/liv.12118

Lee, 2016, Predicting liver-related events using transient elastography in chronic hepatitis c patients with sustained virological response, Gut Liver, 10, 429, 10.5009/gnl150211

Zanetto, 2017, Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals, Liver Transplant, 23, 1103, 10.1002/lt.24790

Ogata, 2017, Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease, Oncology, 93, 92, 10.1159/000470910

Calleja, 2017, Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort, J Hepatol, 66, 1138, 10.1016/j.jhep.2017.01.028

Papatheodoridis, 2016, PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy, J Hepatol, 64, 800, 10.1016/j.jhep.2015.11.035

Yuen, 2009, Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B, J Hepatol, 50, 80, 10.1016/j.jhep.2008.07.023

Yang, 2010, Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection, J Clin Oncol, 28, 2437, 10.1200/JCO.2009.27.4456

Bolondi, 2003, Screening for hepatocellular carcinoma in cirrhosis, J Hepatol, 39, 1076, 10.1016/S0168-8278(03)00349-0

Singal, 2009, Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis, Aliment Pharmacol Ther, 30, 37, 10.1111/j.1365-2036.2009.04014.x

Lencioni, 2008, Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma, J Hepatol, 48, 848, 10.1016/j.jhep.2008.02.005

Pocha, 2013, Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography – a randomised study, Aliment Pharmacol Ther, 38, 303, 10.1111/apt.12370

Runge, 2016, Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus, Invest Radiol, 51, 273, 10.1097/RLI.0000000000000273

Marrero, 2009, Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma, Gastroenterology, 137, 110, 10.1053/j.gastro.2009.04.005

Lok, 2010, Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma, Gastroenterology, 138, 493, 10.1053/j.gastro.2009.10.031

Capurro, 2003, Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma, Gastroenterology, 125, 89, 10.1016/S0016-5085(03)00689-9

Tsukuma, 1993, Risk factors for hepatocellular carcinoma among patients with chronic liver disease, N Engl J Med, 328, 1797, 10.1056/NEJM199306243282501

Chen, 2003, Screening for liver cancer: results of a randomised controlled trial in Qidong, China, J Med Screen, 10, 204, 10.1258/096914103771773320

McMahon, 2001, Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus, Ann Intern Med, 135, 759, 10.7326/0003-4819-135-9-200111060-00006

Biselli, 2015, A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis, Br J Cancer, 112, 69, 10.1038/bjc.2014.536

Di Bisceglie, 2005, Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial, J Hepatol, 43, 434, 10.1016/j.jhep.2005.03.019

Yamashita, 2008, EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma, Cancer Res, 68, 1451, 10.1158/0008-5472.CAN-07-6013

Villanueva, 2010, Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy, Annu Rev Med, 61, 317, 10.1146/annurev.med.080608.100623

Hoshida, 2009, Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res, 69, 7385, 10.1158/0008-5472.CAN-09-1089

Trevisani, 2001, Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status, J Hepatol, 34, 570, 10.1016/S0168-8278(00)00053-2

Nishikawa, 2016, A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation, Medicine, 95, e4832, 10.1097/MD.0000000000004832

Kim, 2015, Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment, Liver Int, 35, 232, 10.1111/liv.12516

Shim, 2014, Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B, J Gastroenterol Hepatol, 29, 1699, 10.1111/jgh.12612

Wong, 2014, On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir, Hepatology, 59, 986, 10.1002/hep.26739

Yang, 2015, Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy, J Gastroenterol Hepatol, 30, 1175, 10.1111/jgh.12921

Sherman, 2001, Alphafetoprotein: an obituary, J Hepatol, 34, 603, 10.1016/S0168-8278(01)00025-3

Koike, 2001, Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients, Cancer, 91, 561, 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N

Sterling, 2007, Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis, Am J Gastroenterol, 102, 2196, 10.1111/j.1572-0241.2007.01405.x

Zhang, 1999, Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer, J Med Screen, 6, 108, 10.1136/jms.6.2.108

Zhang, 2004, Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol, 130, 417, 10.1007/s00432-004-0552-0

Barbara, 1992, Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival, Hepatology, 16, 132, 10.1002/hep.1840160122

Ebara, 1998, Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients, Hepatogastroenterology, 45, 1214

Thompson Coon, 2008, Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis, Br J Cancer, 98, 1166, 10.1038/sj.bjc.6604301

Sheu, 1985, Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications, Gastroenterology, 89, 259, 10.1016/0016-5085(85)90324-5

Trinchet, 2011, Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities, Hepatology, 54, 1987, 10.1002/hep.24545

Santi, 2010, Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival, J Hepatol, 53, 291, 10.1016/j.jhep.2010.03.010

Santagostino, 2003, A 6-month vs. a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus, Blood, 102, 78, 10.1182/blood-2002-10-3310

Cucchetti, 2014, Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma, J Hepatol, 61, 333, 10.1016/j.jhep.2014.03.037

Trevisani, 2002, Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience), Am J Gastroenterol, 97, 734, 10.1111/j.1572-0241.2002.05557.x

Andersson, 2008, Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, 6, 1418, 10.1016/j.cgh.2008.08.005

Bruix, 2001, Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, 35, 421, 10.1016/S0168-8278(01)00130-1

Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933

Matsui, 2011, Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis, Abdom Imaging, 36, 264, 10.1007/s00261-011-9685-1

Burrel, 2003, MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation, Hepatology, 38, 1034, 10.1002/hep.1840380430

Forner, 2008, Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology, 47, 97, 10.1002/hep.21966

Bolondi, 2001, Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis, Gut, 48, 251, 10.1136/gut.48.2.251

Sangiovanni, 2010, The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis, Gut, 59, 638, 10.1136/gut.2009.187286

Mueller C, Waldburger N, Stampfl U, Kauczor H-U, Schirmacher P, Sommer CM, et al. Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut 2017:gutjnl-2017-314981.

Khalili, 2011, Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: An analysis of diagnostic performance and resource utilization, J Hepatol, 54, 723, 10.1016/j.jhep.2010.07.025

Vilana, 2010, Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound, Hepatology, 51, 2020, 10.1002/hep.23600

Galassi, 2013, Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound, Liver Int, 33, 771, 10.1111/liv.12124

Hanna, 2016, Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma, Abdom Radiol, 41, 71, 10.1007/s00261-015-0592-8

Chou, 2015, Imaging techniques for the diagnosis of hepatocellular carcinoma, Ann Intern Med, 162, 697, 10.7326/M14-2509

Lee, 2015, Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis, Radiology, 275, 97, 10.1148/radiol.14140690

Aubé, 2017, EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice, Liver Int, 37, 1515, 10.1111/liv.13429

Rimola, 2012, Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI, J Hepatol, 56, 1317, 10.1016/j.jhep.2012.01.004

Sun, 2010, Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging, Invest Radiol, 45, 96, 10.1097/RLI.0b013e3181c5faf7

Haradome, 2011, Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: Comparison with dynamic triple-phase multidetector CT imaging, J Magn Reson Imaging, 34, 69, 10.1002/jmri.22588

Inoue, 2012, Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity vs. MDCT, J Gastroenterol, 47, 1036, 10.1007/s00535-012-0571-6

Granito, 2013, Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study, Aliment Pharmacol Ther, 37, 355, 10.1111/apt.12166

Tsurusaki, 2016, Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study, J Gastroenterol, 51, 71, 10.1007/s00535-015-1097-5

Hidaka, 2013, The expression of transporter OATP2/OATP8 decreases in undetectable hepatocellular carcinoma by Gd-EOB-MRI in the explanted cirrhotic liver, Hepatol Int, 7, 655, 10.1007/s12072-012-9379-y

Maiwald, 2014, Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?, PLoS One, 9, e111935, 10.1371/journal.pone.0111935

Park, 2014, Dynamic enhancement pattern of HCC smaller than 3cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT, Liver Int, 34, 1593, 10.1111/liv.12550

Chen, 2016, Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma, Magn Reson Med Sci, 15, 49, 10.2463/mrms.2014-0149

Guo, 2016, Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis, Abdom Radiol, 41, 1960, 10.1007/s00261-016-0807-7

Duncan, 2017, Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis, J Magn Reson Imaging, 45, 281, 10.1002/jmri.25345

Ye, 2015, Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma, Medicine, 94, e1157, 10.1097/MD.0000000000001157

Di Martino, 2013, Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging, Eur Radiol, 23, 887, 10.1007/s00330-012-2691-z

Pahade, 2016, Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?, Abdom Radiol, 41, 1270, 10.1007/s00261-016-0635-9

Owens, 2011, Physicians for the CGC of the AC of. High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical Interventions, Ann Intern Med, 154, 174, 10.7326/0003-4819-154-3-201102010-00007

Narita, 2009, Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma, J Gastroenterol, 44, 793, 10.1007/s00535-009-0056-4

Kitao, 2010, Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging–correlation with molecular transporters and histopathologic features, Radiology, 256, 817, 10.1148/radiol.10092214

Joo, 2015, Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?, Eur Radiol, 25, 2859, 10.1007/s00330-015-3686-3

Phongkitkarun, 2013, Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients, World J Gastroenterol, 19, 8357, 10.3748/wjg.v19.i45.8357

Yu, 2014, Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid–enhanced MR Imaging, Radiology, 271, 748, 10.1148/radiol.14131996

Péporté, 2013, Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI, Eur J Radiol, 82, e101, 10.1016/j.ejrad.2012.10.010

Kim, 2015, Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival, Gastroenterology, 148, 1371, 10.1053/j.gastro.2015.02.051

Joo, 2016, Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI, Liver Cancer, 5, 67, 10.1159/000367750

Song, 2015, Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging, Eur Radiol, 25, 2789, 10.1007/s00330-015-3680-9

Davenport, 2013, Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality, Radiology, 266, 452, 10.1148/radiol.12120826

Luetkens, 2015, Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol, Eur Radiol, 25, 3207, 10.1007/s00330-015-3736-x

Park, 2016, Hepatic arterial phase in gadoxetic acid-enhanced liver magnetic resonance imaging, Invest Radiol, 51, 127, 10.1097/RLI.0000000000000211

Terzi, 2018, Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules, J Hepatol, 68, 485, 10.1016/j.jhep.2017.11.007

Li, 2013, Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis, Abdom Imaging, 38, 112, 10.1007/s00261-012-9854-x

Li, 2013, Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis, Abdom Imaging, 38, 112, 10.1007/s00261-012-9854-x

de Sio, 2014, Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study, United Eur Gastroenterol J, 2, 279, 10.1177/2050640614538964

Yuan, 2015, Factors affecting the enhancement patterns of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) and their pathological correlations in patients with a single lesion, Ultraschall Med, 37, 609, 10.1055/s-0034-1399485

Wildner, 2015, CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial, Ultraschall Med, 36, 132, 10.1055/s-0034-1399147

Liu, 2015, Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Liver Cancer, 4, 241, 10.1159/000367738

Wildner, 2014, Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma, Ultraschall Med, 35, 522, 10.1055/s-0034-1385170

Piscaglia, 2017, American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay, Ultraschall Med, 38, 320, 10.1055/s-0042-124661

Piscaglia, 2017, Diagnosis of hepatocellular carcinoma with non-invasive imaging: a plea for worldwide adoption of standard and precise terminology for describing enhancement criteria, Ultraschall Med, 38, 9, 10.1055/s-0042-124204

Iavarone, 2013, Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis, J Hepatol, 58, 1188, 10.1016/j.jhep.2013.02.013

Piscaglia, 2015, Cholangiocarcinoma in cirrhosis: value of hepatocyte specific magnetic resonance imaging, Dig Dis, 33, 735, 10.1159/000439097

Choi, 2017, Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid–enhanced mr imaging and dynamic CT, Radiology, 282, 771, 10.1148/radiol.2016160639

Bolondi, 2013, Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma, Dig Liver Dis, 45, 712, 10.1016/j.dld.2013.01.012

American College of Radiology. CEUS-LI-RADS version 2017. Accessed Mar 15, 2018. https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/CEUS-LI-RADS-2017-Core.pdf?la=en n.d.

Manini MA, Sangiovanni A, Fornari F, Piscaglia F, Biolato M, Fanigliulo L, et al. Clinical and Economical Impact of 2010 AASLD Guidelines for the Diagnosis of Hepatocellular Carcinoma. J Hepatol 2014;60:995–1001.

Furlan, 2012, Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: Intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD), Eur J Radiol, 81, 2099, 10.1016/j.ejrad.2011.07.010

Leoni, 2013, Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?, Ultraschall Med, 34, 280, 10.1055/s-0033-1335024

Bolondi, 2005, Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma, Hepatology, 42, 27, 10.1002/hep.20728

Forner, 2015, Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules, J Hepatol, 62, 150, 10.1016/j.jhep.2014.08.028

Cucchetti, 2013, Cost-effectiveness of hepatic resection vs. percutaneous radiofrequency ablation for early hepatocellular carcinoma, J Hepatol, 59, 300, 10.1016/j.jhep.2013.04.009

Roskams T. Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis 2011;15:245–59, vii–x.

American College of Radiology. Liver Imaging Reporting and Data System version 2017. Accessed Nov 27 2017, from https://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/LIRADS/2017/LIRADS_2017_Core.pdf?la=en n.d.

Darnell, 2015, Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US, Radiology, 275, 698, 10.1148/radiol.15141132

Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143:1253–60-4.

Piscaglia, 2010, Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation, Liver Transpl, 16, 658, 10.1002/lt.22044

Rossi, 2008, Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma, Eur Radiol, 18, 1749, 10.1007/s00330-008-0931-z

Sorrentino, 2011, Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis, J Gastroenterol Hepatol, 26, 669, 10.1111/j.1440-1746.2010.06564.x

Catalano, 2010, Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted mr imaging, Radiology, 254, 154, 10.1148/radiol.09090304

Castilla-Lièvre, 2016, Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, 43, 852, 10.1007/s00259-015-3241-0

Chotipanich, 2016, Diagnosis of hepatocellular carcinoma using C11 CHOLINE PET/CT: comparison with F18 FDG, contrast enhanced MRI and MDCT, Asian Pac J Cancer Prev, 17, 3569

Lin, 2017, Predictive value of 18F-FDG PET/CT for vascular invasion in patients with hepatocellular carcinoma before liver transplantation, Clin Nucl Med, 42, e183, 10.1097/RLU.0000000000001545

Hong, 2016, Alpha-fetoprotein and 18F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation, J Hepatol, 64, 852, 10.1016/j.jhep.2015.11.033

Bosman, F.T., Carneiro, F., Hruban, R.H., Theise ND. WHO Classification of Tumours of the Digestive System. Fourth Edition - WHO - OMS -. Fourth Edi. IARC press; 2010

2009, International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia, Hepatology, 49, 658, 10.1002/hep.22709

Amin MB, Edge SB, American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.

Calderaro, 2017, Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification, J Hepatol, 67, 727, 10.1016/j.jhep.2017.05.014

Ziol, 2017, Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance, Hepatology

Bioulac-Sage, 2017, Hepatocellular adenoma: Classification, variants and clinical relevance, Semin Diagn Pathol, 34, 112, 10.1053/j.semdp.2016.12.007

Clinical, 2016, Practice Guidelines on the management of benign liver tumours, J Hepatol, 65, 386, 10.1016/j.jhep.2016.04.001

Müllhaupt, 2011, Is tumor biopsy necessary?, Liver Transplant, 17, S14, 10.1002/lt.22374

Roskams, 2010, Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis, Semin Liver Dis, 30, 17, 10.1055/s-0030-1247129

Di Tommaso, 2007, Diagnostic value of HSP70, Glypican 3, and Glutamine Synthetase in hepatocellular nodules in cirrhosis, Hepatology, 45, 725, 10.1002/hep.21531

Di Tommaso, 2009, The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma, J Hepatol, 50, 746, 10.1016/j.jhep.2008.11.014

Di Tommaso, 2011, Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma, Hepatology, 53, 1549, 10.1002/hep.24218

Tremosini, 2012, Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma, Gut, 61, 1481, 10.1136/gutjnl-2011-301862

Durnez, 2006, The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin, Histopathology, 49, 138, 10.1111/j.1365-2559.2006.02468.x

Villanueva, 2011, Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma, Gastroenterology, 140, 1501, 10.1053/j.gastro.2011.02.006

Nault, 2013, A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection, Gastroenterology, 145, 176, 10.1053/j.gastro.2013.03.051

Miltiadous, 2015, Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation, J Hepatol, 63, 1368, 10.1016/j.jhep.2015.07.025

Rebouissou, 2017, Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro, Clin Cancer Res, 23, 4364, 10.1158/1078-0432.CCR-16-3118

Silva, 2008, Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis, Gut, 57, 1592, 10.1136/gut.2008.149062

Fuks, 2014, Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC, J Hepatol, 61, 589, 10.1016/j.jhep.2014.04.046

Rockey, 2009, Liver biopsy, Hepatology, 49, 1017, 10.1002/hep.22742

Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 30, 52, 10.1055/s-0030-1247132

Livraghi, 2008, Sustained complete response and complications rate after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis. Is resection still the treatment of choice?, Hepatology, 47, 82, 10.1002/hep.21933

Kuang, 2011, Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma, J Gastrointest Surg, 15, 2165, 10.1007/s11605-011-1716-2

D’Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, J Hepatol, 44, 217, 10.1016/j.jhep.2005.10.013

Okuda, 1985, Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients, Cancer, 56, 918, 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E

A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751–5.

Llovet, 1999, Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials, Hepatology, 29, 62, 10.1002/hep.510290145

Villa, 2000, Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival, Hepatology, 32, 233, 10.1053/jhep.2000.9603

Cabibbo, 2010, A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma, Hepatology, 51, 1274, 10.1002/hep.23485

Llovet, 1998, Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power, Hepatology, 27, 1572, 10.1002/hep.510270616

Chan ACY, Fan ST, Poon RTP, Cheung TT, Chok KSH, Chan SC, et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour?node?metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB 2013;15:439–48.

Chevret, 1999, A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire, J Hepatol, 31, 133, 10.1016/S0168-8278(99)80173-1

Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 19, 329, 10.1055/s-2007-1007122

Leung, 2002, Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients, Cancer, 94, 1760, 10.1002/cncr.10384

Yau, 2014, Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma, Gastroenterology, 146, 1691, 10.1053/j.gastro.2014.02.032

Kitai, 2008, Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score, Oncology, 75, 83, 10.1159/000173428

Sohn, 2017, Validation of the Hong Kong liver cancer staging system in determining prognosis of the north american patients following intra-arterial therapy, Clin Gastroenterol Hepatol, 15, 746, 10.1016/j.cgh.2016.10.036

Sherman, 2014, Staging for hepatocellular carcinoma: complex and confusing, Gastroenterology, 146, 1599, 10.1053/j.gastro.2014.04.026

Marrero, 2005, Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort, Hepatology, 41, 707, 10.1002/hep.20636

Cillo, 2004, The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?, J Hepatol, 40, 124, 10.1016/j.jhep.2003.09.027

Guglielmi, 2008, Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response, Am J Gastroenterol, 103, 597, 10.1111/j.1572-0241.2007.01604.x

Vitale, 2009, Validation of the BCLC prognostic system in surgical hepatocellular cancer patients, Transplant Proc, 41, 1260, 10.1016/j.transproceed.2009.03.054

Llovet, 2003, Hepatocellular carcinoma, Lancet, 362, 1907, 10.1016/S0140-6736(03)14964-1

Llovet, 2008, Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, 100, 698, 10.1093/jnci/djn134

Forner, 2012, Hepatocellular carcinoma, Lancet, 379, 1245, 10.1016/S0140-6736(11)61347-0

Simon, 2009, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, 101, 1446, 10.1093/jnci/djp335

Pinyol, 2017, Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial, J Hepatol, 66, S12, 10.1016/S0168-8278(17)30287-8

Johnson, 2015, Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade, J Clin Oncol, 33, 550, 10.1200/JCO.2014.57.9151

Pinato, 2017, The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma, J Hepatol, 66, 338, 10.1016/j.jhep.2016.09.008

Imamura, 2003, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy, J Hepatol, 38, 200, 10.1016/S0168-8278(02)00360-4

Ikai, 2004, Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey, Cancer, 101, 796, 10.1002/cncr.20426

Vibert, 2010, Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor, Am J Transpl, 10, 129, 10.1111/j.1600-6143.2009.02750.x

Merani, 2011, The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma, J Hepatol, 55, 814, 10.1016/j.jhep.2010.12.040

Toso, 2012, A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list, Hepatology, 56, 149, 10.1002/hep.25603

Duvoux, 2012, Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria, Gastroenterology, 143, 985, 10.1053/j.gastro.2012.05.052

Piñero, 2016, Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America, Uruguay Liver Int, 36, 1657, 10.1111/liv.13159

Toso, 2015, Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation, Hepatology, 62, 158, 10.1002/hep.27787

Notarpaolo, 2017, Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC, J Hepatol, 66, 552, 10.1016/j.jhep.2016.10.038

Mazzaferro, 2018, Metroticket 2.0 model for analysis of competing risks of death following liver transplantation for hepatocellular carcinoma, Gastroenterology, 154, 128, 10.1053/j.gastro.2017.09.025

Livraghi, 1995, Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection, Radiology, 197, 101, 10.1148/radiology.197.1.7568806

N’Kontchou, 2009, Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis, Hepatology, 50, 1475, 10.1002/hep.23181

Takayasu, 2012, Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines, J Hepatol, 56, 886, 10.1016/j.jhep.2011.10.021

Llovet, 2012, Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma, Clin Cancer Res, 18, 2290, 10.1158/1078-0432.CCR-11-2175

Zhu, 2015, Ramucirumab vs. placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 16, 859, 10.1016/S1470-2045(15)00050-9

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015;45:n/a-n/a.

Hasegawa, 2013, Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey, J Hepatol, 58, 724, 10.1016/j.jhep.2012.11.009

Roayaie, 2013, Resection of hepatocellular cancer ≤2 cm: Results from two Western centers, Hepatology, 57, 1426, 10.1002/hep.25832

Cho, 2010, Hepatic resection vs. radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis, Hepatology, 51, 1284, 10.1002/hep.23466

Sala, 2004, High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation, Liver Transpl, 10, 1294, 10.1002/lt.20202

Fuks, 2012, Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis, Hepatology, 55, 132, 10.1002/hep.24680

Rodríguez de Lope, 2012, Management of HCC, J Hepatol, 56, S75, 10.1016/S0168-8278(12)60009-9

Forner, 2010, Current strategy for staging and treatment: the BCLC update and future prospects, Semin Liver Dis, 30, 61, 10.1055/s-0030-1247133

Llovet, 1999, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection vs. transplantation, Hepatology, 30, 1434, 10.1002/hep.510300629

Ishizawa, 2008, Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma, Gastroenterology, 134, 1908, 10.1053/j.gastro.2008.02.091

Berzigotti, 2015, Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis, Hepatology, 61, 526, 10.1002/hep.27431

Lencioni, 2005, Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation, Radiology, 234, 961, 10.1148/radiol.2343040350

Choi, 2007, Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series, Eur Radiol, 17, 684, 10.1007/s00330-006-0461-5

Sala, 2004, Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma, Hepatology, 40, 1352, 10.1002/hep.20465

Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047

Beaugrand, 2005, Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an International randomized double-blind placebo-controlled study in 747 patients, J Hepatol, 42, 17A, 10.1016/S0168-8278(05)81449-7

Llovet, 2002, Arterial embolisation or chemoembolisation vs. symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016/S0140-6736(02)08649-X

Lo, 2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053/jhep.2002.33156

Burrel, 2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design, J Hepatol, 56, 1330, 10.1016/j.jhep.2012.01.008

Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis. Cardiovasc Interv Radiol 2012;Oct;35:1119–28.

Bolondi, 2012, Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions, Semin Liver Dis, 32, 348

Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 2014;61:1287–1296.

Bruix, 2011, Management of hepatocellular carcinoma: An update, Hepatology, 53, 1020, 10.1002/hep.24199

Tsochatzis, 2014, Liver cirrhosis, Lancet, 17, 1749, 10.1016/S0140-6736(14)60121-5

Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857

Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7

Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;Jan 7;389:56–66.

Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet n.d.; 2018: In press.

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry A, Rimassa L, Ryoo B-Y, et al. Cabozantinib (C) vs. placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. J Clin Oncol 2018;36:abstr 2017.

Raoul, 2011, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treat Rev, 37, 212, 10.1016/j.ctrv.2010.07.006

Forner, 2014, Treatment of intermediate-stage hepatocellular carcinoma, Nat Rev Clin Oncol, 11, 525, 10.1038/nrclinonc.2014.122

Huitzil-Melendez, 2010, Advanced hepatocellular carcinoma: which staging systems best predict prognosis?, J Clin Oncol, 28, 2889, 10.1200/JCO.2009.25.9895

Lang, 2005, Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis, Br J Surg, 92, 198, 10.1002/bjs.4763

Ertle, 2011, Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis, Int J Cancer, 128, 2436, 10.1002/ijc.25797

Viganò, 2015, Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC, J Hepatol, 63, 93, 10.1016/j.jhep.2015.01.024

Cauchy, 2013, Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome, Br J Surg, 100, 113, 10.1002/bjs.8963

Makuuchi, 2004, The surgical approach to HCC: our progress and results in Japan, Liver Transpl, 10, S46, 10.1002/lt.20044

Child, 1964, Surgery and portal hypertension, Major Probl Clin Surg, 1, 1

Pugh, 1973, Transection of the oesophagus for bleeding oesophageal varices, Br J Surg, 60, 646, 10.1002/bjs.1800600817

Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003;138:1198–206; discussion 1206.

Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012;256:706–12-3.

Donadon, 2015, Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score, World J Surg, 39, 237, 10.1007/s00268-014-2786-6

De, 2016, Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery?, World J Hepatol, 8, 355, 10.4254/wjh.v8.i7.355

Lisotti, 2014, Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis, Hepatology, 59, 643, 10.1002/hep.26700

Rahbari, 2011, Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS), HPB, 13, 528, 10.1111/j.1477-2574.2011.00319.x

Llop, 2012, Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors, J Hepatol, 56, 103, 10.1016/j.jhep.2011.06.027

Wong JS-W, Wong GL-H, Chan AW-H, Wong VW-S, Cheung Y-S, Chong C-N, et al. Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. Ann Surg 2013;257:922–8.

Nishio, 2016, Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma, Surgery, 159, 399, 10.1016/j.surg.2015.06.024

Zipprich, 2010, Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis, Gut, 59, 963, 10.1136/gut.2010.208595

Wagener, 2013, Assessment of hepatic function, operative candidacy, and medical management after liver resection in the patient with underlying liver disease, Semin Liver Dis, 33, 204, 10.1055/s-0033-1351777

Cucchetti, 2009, Is portal hypertension a contraindication to hepatic resection?, Ann Surg, 250, 922, 10.1097/SLA.0b013e3181b977a5

Roayaie, 2015, The role of hepatic resection in the treatment of hepatocellular cancer, Hepatology, 62, 440, 10.1002/hep.27745

Citterio, 2016, Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma, JAMA Surg, 151, 846, 10.1001/jamasurg.2016.1121

Strasberg, 2000, Hpb EG-, 2000 U. The Brisbane 2000 terminology of liver anatomy and resections, HBP, 2000, 333

Shindoh, 2015, Surgical approach for hepatitis C virus-related hepatocellular carcinoma, World J Hepatol, 7, 70, 10.4254/wjh.v7.i1.70

Eguchi, 2008, Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey, Surgery, 143, 469, 10.1016/j.surg.2007.12.003

Twaij, 2014, Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: Systematic review and meta-analysis, World J Gastroenterol, 20, 8274, 10.3748/wjg.v20.i25.8274

Franken, 2014, Comparison of short-term outcomes in laparoscopic vs. open hepatectomy, JAMA Surg, 149, 941, 10.1001/jamasurg.2014.1023

Ciria, 2016, Comparative Short-term Benefits of Laparoscopic Liver Resection: 9000 Cases and Climbing, Ann Surg, 263, 761, 10.1097/SLA.0000000000001413

Han, 2015, Laparoscopic vs. open liver resection for hepatocellular carcinoma: Case - matched study with propensity score matching, J Hepatol, 63, 643, 10.1016/j.jhep.2015.04.005

Sposito, 2016, Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma, Br J Surg, 103, 871, 10.1002/bjs.10137

Cucchetti, 2016, Effect of age on survival in patients undergoing resection of hepatocellular carcinoma, Br J Surg, 103, e93, 10.1002/bjs.10056

Vitale, 2015, Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study, J Hepatol, 62, 617, 10.1016/j.jhep.2014.10.037

Soubrane, 2014, Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients, HPB, 16, 357, 10.1111/hpb.12142

Parks KR, Kuo Y-H, Davis JM, O’ Brien B, Hagopian EJ. Laparoscopic vs. open liver resection: a meta-analysis of long-term outcome. HPB (Oxford) 2014;16:109–18.

Morise, 2015, Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease, J Hepatobiliary Pancreat Sci, 22, 342, 10.1002/jhbp.215

Takahara, 2015, Long-term and perioperative outcomes of laparoscopic vs. open liver resection for hepatocellular carcinoma with propensity score matching: a multi-institutional Japanese study, J Hepatobiliary Pancreat Sci, 22, 721, 10.1002/jhbp.276

Abu Hilal, 2017, The southampton consensus guidelines for laparoscopic liver surgery, Ann Surg, 10.1097/SLA.0000000000002524

Chen, 2006, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann Surg, 243, 321, 10.1097/01.sla.0000201480.65519.b8

Feng, 2012, A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma, J Hepatol, 57, 794, 10.1016/j.jhep.2012.05.007

Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, et al. Randomized clinical trial of hepatic resection vs. radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017;Dec;104:1775–84.

Huang, 2010, A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria, Ann Surg, 252, 903, 10.1097/SLA.0b013e3181efc656

Wang, 2014, Radiofrequency ablation vs. hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials, PLoS One, 9, e84484, 10.1371/journal.pone.0084484

Xin, 2016, Percutaneous radiofrequency ablation vs. surgical resection for the treatment of small hepatic carcinoma: a meta-analysis, Am J Cancer Prev, 4, 13

Cucchetti, 2014, An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma, Dig Liver Dis, 46, 257, 10.1016/j.dld.2013.10.015

Wakabayashi, 2015, Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka, Ann Surg, 261, 619

Cheek, 2016, Evidence supporting laparoscopic major hepatectomy, J Hepatobiliary Pancreat Sci, 23, 257, 10.1002/jhbp.338

Lencioni, 2012, Local-regional treatment of hepatocellular carcinoma, Radiology, 262, 43, 10.1148/radiol.11110144

Qi, 2013, Radiofrequency ablation vs. hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials, J Clin Gastroenterol, 48, 450, 10.1097/MCG.0000000000000008

Nathan, 2013, Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis, Ann Surg, 258, 1022, 10.1097/SLA.0b013e31827da749

Torzilli, 2013, A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers, Ann Surg, 257, 929, 10.1097/SLA.0b013e31828329b8

Yin, 2014, Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT, J Hepatol, 61, 82, 10.1016/j.jhep.2014.03.012

Zhong, 2013, Comparison of long-term survival of patients with bclc stage b hepatocellular carcinoma after liver resection or transarterial chemoembolization, PLoS One, 8, e68193, 10.1371/journal.pone.0068193

Díaz-González, 2016, Treatment of hepatocellular carcinoma, Dig Dis, 34, 597, 10.1159/000445275

Shi, 2010, Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus, Ann Surg Oncol, 17, 2073, 10.1245/s10434-010-0940-4

Lau, 2013, Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90, Oncology, 84, 311, 10.1159/000348325

Mazzaferro, 2013, Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study, Hepatology, 57, 1826, 10.1002/hep.26014

Kokudo, 2016, Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion, J Hepatol, 65, 938, 10.1016/j.jhep.2016.05.044

Kokudo, 2017, Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey, Hepatology, 66, 510, 10.1002/hep.29225

Pawlik, 2005, Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: Results of a multicenter study, Surgery, 137, 403, 10.1016/j.surg.2004.12.012

Chirica M, Scatton O, Massault P-P, Aloia T, Randone B, Dousset B, et al. Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery? Arch Surg 2008;143:538–43; discussion 543.

Roayaie, 2013, Resection of hepatocellular carcinoma with macroscopic vascular invasion, Ann Surg Oncol, 20, 3754, 10.1245/s10434-013-3074-7

Pesi, 2015, Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study, Am J Surg, 210, 35, 10.1016/j.amjsurg.2014.09.041

Mazzaferro, 2006, Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis, Hepatology, 44, 1543, 10.1002/hep.21415

Shen, 2010, Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach, J Hepatol, 52, 889, 10.1016/j.jhep.2009.12.041

Samuel M, Chow PK-H, Chan Shih-Yen E, Machin D, Soo K-C. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009:CD001199.

Takayama, 2000, Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial, Lancet, 356, 802, 10.1016/S0140-6736(00)02654-4

Lee, 2015, Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma, Gastroenterology, 148, 1383, 10.1053/j.gastro.2015.02.055

Bruix, 2015, Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet Oncol, 16, 1344, 10.1016/S1470-2045(15)00198-9

Mazzaferro, 2016, The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors, Am J Transplant, 16, 2892, 10.1111/ajt.13831

Mazzaferro, 2018, Pro (With Caution): Extended oncologic indications in liver transplantation, Liver Transplant, 24, 98, 10.1002/lt.24963

Kim, 2017, OPTN/SRTR 2015 annual data report: liver, Am J Transplant, 17, 174, 10.1111/ajt.14126

Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104

Clavien P-AP-A, Lesurtel M, Bossuyt PMM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11–22.

Mazzaferro, 2011, Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience, Liver Transplant, 17, S44, 10.1002/lt.22365

Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002/hep.29086

Yao, 2001, Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival, Hepatology, 33, 1394, 10.1053/jhep.2001.24563

Yao, 2007, Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging, Am J Transpl, 7, 2587, 10.1111/j.1600-6143.2007.01965.x

Mazzaferro, 2009, Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol, 10, 35, 10.1016/S1470-2045(08)70284-5

Toso, 2009, Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database, Hepatology, 49, 832, 10.1002/hep.22693

Zheng, 2008, Liver transplantation for hepatocellular carcinoma: hangzhou experiences, Transplantation, 85, 1726, 10.1097/TP.0b013e31816b67e4

Yang, 2007, A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma, Surgery, 141, 598, 10.1016/j.surg.2006.11.006

Ravaioli, 2008, Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria, Am J Transpl, 8, 2547, 10.1111/j.1600-6143.2008.02409.x

Levi, 2010, Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era, J Am Coll Surg, 210, 727, 10.1016/j.jamcollsurg.2010.01.007

Grąt, 2016, Relevance of pre-transplant α-fetoprotein dynamics in liver transplantation for hepatocellular cancer, Ann Transplant, 21, 115, 10.12659/AOT.894644

Lai, 2012, Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation, Clin Transplant, 26, E125, 10.1111/j.1399-0012.2011.01572.x

Yao, 2015, Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria, Hepatology, 61, 1968, 10.1002/hep.27752

Berry, 2013, Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma, Liver Transplant, 19, 634, 10.1002/lt.23652

Andreou, 2016, Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation, Clin Transplant, 30, 819, 10.1111/ctr.12755

Murali, 2017, Locoregional therapy with curative intent vs. primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis, Transplantation, 101, e249, 10.1097/TP.0000000000001730

Fondevila, 2014, A bridge too far: We have not overstepped the line for extended deceased donors, Liver Transpl, 20, S9, 10.1002/lt.24000

Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017;Apr;14:203–17.

Gruttadauria, 2008, Critical use of extended criteria donor liver grafts in adult-to-adult whole liver transplantation: A single-center experience, Liver Transplant, 14, 220, 10.1002/lt.21359

Barbier, 2016, Liver transplantation with older donors: a comparison with younger donors in a context of organ shortage, Transplantation, 100, 2410, 10.1097/TP.0000000000001401

Khorsandi, 2016, Does donation after cardiac death utilization adversely affect hepatocellular cancer survival?, Transplantation, 100, 1916, 10.1097/TP.0000000000001150

Orci, 2015, Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation, Br J Surg, 102, 1250, 10.1002/bjs.9868

Mehta, 2013, Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy, Liver Transpl, 19, 1343, 10.1002/lt.23753

Heimbach, 2015, Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States, Hepatology, 61, 1643, 10.1002/hep.27704

UNOS-OPTN. OPTN Policies Policy 9: Allocation of Livers and Liver-Intestines. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_09 (accessed December 30, 2017) n.d.

Vitale, 2014, A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list, J Hepatol, 60, 290, 10.1016/j.jhep.2013.10.010

Marvin, 2015, MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma, Liver Transpl, 21, 612, 10.1002/lt.24098

Halazun, 2014, Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment, Hepatology, 60, 1957, 10.1002/hep.27272

Bittermann, 2014, Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach, Am J Transplant, 14, 79, 10.1111/ajt.12530

Samoylova, 2014, Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation, Liver Transplant, 20, 937, 10.1002/lt.23902

Mazzaferro, 2016, Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach, Hepatology, 63, 1707, 10.1002/hep.28420

Montalti, 2014, Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation, Transplantation, 97, 220, 10.1097/TP.0b013e3182a8607e

Cillo, 2015, A multistep, consensus-based approach to organ allocation in liver transplantation: toward a “Blended Principle Model”, Am J Transplant, 15, 2552, 10.1111/ajt.13408

Bhat, 2017, Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics, J Hepatol, 66, 374, 10.1016/j.jhep.2016.10.008

Flemming, 2017, Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy, Hepatology, 65, 804, 10.1002/hep.28923

Roccaro, 2017, Early detection of hepatocellular carcinoma after treatment with direct-acting antivirals: selection bias or biologically plausible?, Gastroenterology, 152, 2072, 10.1053/j.gastro.2017.04.041

Viganò, 2017, Treatment of hepatitis C virus infection in Italy: A consensus report from an expert panel, Dig Liver Dis, 49, 731, 10.1016/j.dld.2017.03.027

Bruix, 2014, Hepatocellular carcinoma: clinical frontiers and perspectives, Gut, 63, 844, 10.1136/gutjnl-2013-306627

Berry, 2015, Comparison of liver transplant-related survival benefit in patients with vs. without hepatocellular carcinoma in the United States, Gastroenterology, 149, 669, 10.1053/j.gastro.2015.05.025

Schaubel, 2009, Survival benefit-based deceased-donor liver allocation, Am J Transplant, 9, 970, 10.1111/j.1600-6143.2009.02571.x

Vitale, 2011, Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study, Lancet Oncol, 12, 654, 10.1016/S1470-2045(11)70144-9

Berry, 2012, Are patients with Child’s a cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation?, Am J Transplant, 12, 706, 10.1111/j.1600-6143.2011.03853.x

Hsu, 2009, Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score, World J Surg, 33, 2412, 10.1007/s00268-009-0202-4

Roberts, 2010, Hepatocellular carcinoma: Ablate and wait vs. rapid transplantation, Liver Transpl, 16, 925, 10.1002/lt.22103

Cucchetti, 2011, Improved diagnostic imaging and interventional therapies prolong survival after resection for hepatocellular carcinoma in cirrhosis: the university of bologna experience over 10 years, Ann Surg Oncol, 18, 1630, 10.1245/s10434-010-1463-8

Vibert, 2010, Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor, Am J Transplant, 10, 129, 10.1111/j.1600-6143.2009.02750.x

Agopian VG, Harlander-Locke MP, Markovic D, Dumronggittigule W, Xia V, Kaldas FM, et al. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model. JAMA Surg 2017.

Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, et al. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Interv Radiol n.d.; 35:1094–101.

Tsochatzis, 2013, Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma, Liver Int, 33, 944, 10.1111/liv.12144

Parikh, 2015, Downstaging hepatocellular carcinoma: A systematic review and pooled analysis, Liver Transplant, 21, 1142, 10.1002/lt.24169

Decaens, 2006, Impact of UCSF criteria according to pre- and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time, Liver Transpl, 12, 1761, 10.1002/lt.20884

Llovet, 2002, Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation, Gut, 50, 123, 10.1136/gut.50.1.123

Lei, 2013, Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria, J Gastrointest Surg, 17, 1440, 10.1007/s11605-013-2229-y

Bova, 2013, Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies, Cardiovasc Intervent Radiol, 36, 433, 10.1007/s00270-012-0458-1

Tsuchiya, 2014, Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma, Liver Transpl, 20, 291, 10.1002/lt.23798

Finkenstedt, 2016, Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy, Liver Int, 36, 688, 10.1111/liv.12966

Terzi, 2015, Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation, Liver Transpl, 21, 248, 10.1002/lt.24041

Kim, 2015, Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization, J Hepatol, 62, 1076, 10.1016/j.jhep.2014.12.013

Barakat, 2010, Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis, Liver Transpl, 16, 289, 10.1002/lt.21994

Chapman, 2008, Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation, Ann Surg, 248, 617, 10.1097/SLA.0b013e31818a07d4

Nadalin, 2016, Living donor liver transplantation in Europe, Hepatobiliary Surg Nutr, 5, 159

Fisher, 2007, Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation, Am J Transpl, 7, 1601, 10.1111/j.1600-6143.2007.01802.x

Hong, 2016, Living donor liver transplantation for hepatocellular carcinoma in Seoul National University, HepatoBiliary Surg Nutr, 5, 453, 10.21037/hbsn.2016.08.07

Lee, 2017, Macrovascular invasion is not an absolute contraindication for living donor liver transplantation, Liver Transplant, 23, 19, 10.1002/lt.24610

Lim, 2014, Mistargeting after fusion imaging-guided percutaneous radiofrequency ablation of hepatocellular carcinomas, J Vasc Interv Radiol, 25, 307, 10.1016/j.jvir.2013.10.025

Hakime, 2012, Electromagnetic-tracked biopsy under ultrasound guidance: preliminary results, Cardiovasc Intervent Radiol, 35, 898, 10.1007/s00270-011-0278-8

Abdel-Rehim, 2015, Assessment of liver ablation using cone beam computed tomography, World J Gastroenterol, 21, 517, 10.3748/wjg.v21.i2.517

Dietrich, 2016, EFSUMB guidelines on interventional ultrasound (INVUS), part III – abdominal treatment procedures (Short Version), Ultraschall Med, 37, 27, 10.1055/s-0035-1553965

Pompili, 2015, Single hepatocellular carcinoma smaller than 2 cm: are ethanol injection and radiofrequency ablation equally effective?, Anticancer Res, 35, 325

Germani, 2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis, J Hepatol, 52, 380, 10.1016/j.jhep.2009.12.004

Cho, 2009, Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology, 49, 453, 10.1002/hep.22648

Orlando, 2009, Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials, Am J Gastroenterol, 104, 514, 10.1038/ajg.2008.80

Huo, 2003, Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study, Scand J Gastroenterol, 38, 770, 10.1080/00365520310003048

Schoppmeyer K, Weis S, Mössner J, Fleig WE. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2009:CD006745.

Lee, 2014, Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis, Radiology, 270, 900, 10.1148/radiol.13130940

Kang, 2016, Long-term therapeutic outcomes of radiofrequency ablation for subcapsular vs. nonsubcapsular hepatocellular carcinoma: a propensity score matched study, Radiology, 280, 300, 10.1148/radiol.2016151243

Francica, 2016, Radiofrequency and microwave ablation of subcapsular hepatocellular carcinoma accessed by direct puncture: Safety and efficacy, Eur J Radiol, 85, 739, 10.1016/j.ejrad.2016.01.020

Seror, 2008, Large (>or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes–initial experience in 26 patients, Radiology, 248, 288, 10.1148/radiol.2481071101

Seror, 2016, Hepatocellular carcinoma within Milan criteria: no-touch multibipolar radiofrequency ablation for treatment-long-term results, Radiology, 280, 981, 10.1148/radiol.2016164017

Cartier, 2016, Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?, J Gastroenterol Hepatol, 31, 654, 10.1111/jgh.13179

Wang, 2016, Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis, Korean J Radiol, 17, 93, 10.3348/kjr.2016.17.1.93

Lan, 2016, Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma, Medicine, 95, e3185, 10.1097/MD.0000000000003185

Qi, 2016, Management of hepatocellular carcinoma: anoverview of major findings from meta-analyses, Oncotarget, 7, 34703, 10.18632/oncotarget.9157

Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011650.

Leoni, 2014, Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group, Dig Liver Dis, 46, 549, 10.1016/j.dld.2014.02.012

Poulou, 2015, Percutaneous microwave ablation vs. radiofrequency ablation in the treatment of hepatocellular carcinoma, World J Hepatol, 7, 1054, 10.4254/wjh.v7.i8.1054

Facciorusso, 2016, Microwave ablation vs. radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis, Int J Hyperthermia, 32, 339, 10.3109/02656736.2015.1127434

Brunello, 2013, Radiofrequency ablation: technical and clinical long-term outcomes for single hepatocellular carcinoma up to 30 mm, Eur J Gastroenterol Hepatol, 25, 842, 10.1097/MEG.0b013e32835ee5f1

Hoffmann, 2013, Comparison of four microwave ablation devices: an experimental study in ex vivo bovine liver, Radiology, 268, 89, 10.1148/radiol.13121127

Di Costanzo, 2015, Radiofrequency ablation vs. laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial, J Gastroenterol Hepatol, 30, 559, 10.1111/jgh.12791

Francica, 2012, Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location, AJR Am J Roentgenol, 199, 1393, 10.2214/AJR.11.7850

Wang, 2015, Multicenter randomized controlled trial of percutaneous cryoablation vs. radiofrequency ablation in hepatocellular carcinoma, Hepatology, 61, 1579, 10.1002/hep.27548

Cheng, 2015, Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis, J Vasc Interv Radiol, 26, 1184, 10.1016/j.jvir.2015.05.014

Sutter, 2017, Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series, Radiology, 284, 877, 10.1148/radiol.2017161413

Zhang, 2009, High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins, Eur Radiol, 19, 437, 10.1007/s00330-008-1137-0

Ng, 2011, High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience, Ann Surg, 253, 981, 10.1097/SLA.0b013e3182128a8b

Nabavizadeh, 2017, Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis, Lancet Oncol, 18, e192, 10.1016/S1470-2045(17)30162-6

Huo, 2015, Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis, JAMA Oncol, 1, 756, 10.1001/jamaoncol.2015.2189

Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011314.

Bush, 2016, Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis, Int J Radiat Oncol, 95, 477, 10.1016/j.ijrobp.2016.02.027

Cha, 2017, Clinical practice patterns of radiotherapy in patients with hepatocellular carcinoma: a Korean radiation oncology group study (KROG 14–07), Cancer Res Treat, 49, 61, 10.4143/crt.2016.097

Im, 2017, Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area, Liver Int, 37, 90, 10.1111/liv.13191

Choi, 2017, The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus, Liver Transpl, 23, 545, 10.1002/lt.24729

Jeong, 2017, Liver transplantation after transarterial chemoembolization and radiotherapy for hepatocellular carcinoma with vascular invasion, J Gastrointest Surg, 21, 275, 10.1007/s11605-016-3302-0

Berger, 2017, External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database, J Surg Oncol, 116, 307, 10.1002/jso.24661

Sapisochin, 2017, Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis, J Hepatol, 67, 92, 10.1016/j.jhep.2017.02.022

Park, 2014, Current practice and future clinical trials, Liver Cancer, 2016, 162

Keane, 2016, Liver-directed radiotherapy for hepatocellular carcinoma, Liver Cancer, 5, 198, 10.1159/000367764

Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 2017.

Park, 2015, Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, Liver Int, 35, 2155, 10.1111/liv.12818

Sangro, 2011, Transarterial therapies for hepatocellular carcinoma, Expert Opin Pharmacother, 12, 1057, 10.1517/14656566.2011.545346

Sangro, 2014, Transarterial chemoembolization and radioembolization, Semin Liver Dis, 34, 435, 10.1055/s-0034-1394142

de Baere, 2016, Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion, Cardiovasc Intervent Radiol, 39, 334, 10.1007/s00270-015-1208-y

Takayasu, 2010, Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis, AJR Am J Roentgenol, 194, 830, 10.2214/AJR.09.3308

Lencioni, 2016, Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data, Hepatology, 64, 106, 10.1002/hep.28453

Boulin, 2011, Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma, Anticancer Drugs, 22, 741, 10.1097/CAD.0b013e328346a0c5

Boulin, 2016, Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin, Eur Radiol, 26, 601, 10.1007/s00330-015-3855-4

Cammà, 2002, Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials, Radiology, 224, 47, 10.1148/radiol.2241011262

Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;3:CD004787.

Ogasawara, 2017, A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization, Hepatology

Varela, 2007, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J Hepatol, 46, 474, 10.1016/j.jhep.2006.10.020

Lammer, 2010, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Interv Radiol, 33, 41, 10.1007/s00270-009-9711-7

Golfieri, 2014, Randomised controlled trial of doxorubicin-eluting beads vs. conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer, 111, 255, 10.1038/bjc.2014.199

Gao, 2013, Doxorubicin-eluting bead vs. conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis, Hepatogastroenterology, 60, 813

Monier, 2017, Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion, Eur Radiol, 27, 1431, 10.1007/s00330-016-4488-y

Silva, 2017, Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis, HPB, 19, 659, 10.1016/j.hpb.2017.04.016

Ronot, 2016, Cone-beam CT angiography for determination of tumor-feeding vessels during chemoembolization of liver tumors: comparison of conventional and dedicated-software analysis, J Vasc Interv Radiol, 27, 32, 10.1016/j.jvir.2015.09.010

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256–61.

Sieghart, 2013, The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, 57, 2261, 10.1002/hep.26256

Hucke, 2014, The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE, J Hepatol, 60, 118, 10.1016/j.jhep.2013.08.022

Adhoute, 2015, Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process, J Hepatol, 62, 855, 10.1016/j.jhep.2014.11.014

Kadalayil, 2013, A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer, Ann Oncol, 24, 2565, 10.1093/annonc/mdt247

Arizumi, 2015, Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma, Oncology, 89, 4, 10.1159/000440625

Kudo, 2014, Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, 59, 2424, 10.1002/hep.26760

Terzi, 2014, The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series, Dig Dis, 32, 711, 10.1159/000368007

Pipa-Muñiz, 2017, The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study, Gastroenterol Hepatol, 40, 515, 10.1016/j.gastrohep.2017.05.009

Peng, 2013, Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial, J Clin Oncol, 31, 426, 10.1200/JCO.2012.42.9936

Iezzi, 2015, Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma, Dig Liver Dis, 47, 242, 10.1016/j.dld.2014.12.007

Lencioni, 2016, Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial, J Hepatol, 64, 1090, 10.1016/j.jhep.2016.01.012

Chao, 2015, The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial, Int J Cancer, 136, 1458, 10.1002/ijc.29126

Meyer, 2017, Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial, Lancet Gastroenterol Hepatol, 2, 565, 10.1016/S2468-1253(17)30156-5

Kudo, 2014, Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial, Hepatology, 60, 1697, 10.1002/hep.27290

Kudo, 2018, Orantinib vs. placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study, Lancet Gastroenterol Hepatol, 3, 37, 10.1016/S2468-1253(17)30290-X

Marelli, 2007, Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies, Cardiovasc Intervent Radiol, 30, 6, 10.1007/s00270-006-0062-3

Xie, 2014, Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review, Tumour Biol, 35, 8451, 10.1007/s13277-014-2340-z

Meyer, 2013, A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs. embolisation alone for hepatocellular carcinoma, Br J Cancer, 108, 1252, 10.1038/bjc.2013.85

Brown, 2016, Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone, J Clin Oncol, 34, 2046, 10.1200/JCO.2015.64.0821

Pomfret, 2010, Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States, Liver Transpl, 16, 262, 10.1002/lt.21999

Bargellini, 2014, Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology, Cardiovasc Intervent Radiol, 37, 438, 10.1007/s00270-013-0656-5

Terzi, 2012, Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”, J Hepatol, 57, 1258, 10.1016/j.jhep.2012.07.025

Raoul, 1997, Prospective randomized trial of chemoembolization vs. intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma, Hepatology, 26, 1156

Kulik, 2008, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology, 47, 71, 10.1002/hep.21980

Salem, 2010, Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 138, 52, 10.1053/j.gastro.2009.09.006

Sangro, 2011, Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, 54, 868, 10.1002/hep.24451

Hilgard, 2010, Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, 52, 1741, 10.1002/hep.23944

Golfieri, 2013, Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma, J Hepatol, 59, 753, 10.1016/j.jhep.2013.05.025

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;Dec;18:1624–36.

Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: Selective Internal Radiation Therapy vs. Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018:JCO.2017.76.089.

Salem, 2011, Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology, 140, 497, 10.1053/j.gastro.2010.10.049

Salem, 2013, Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization, Clin Gastroenterol Hepatol, 11, 1358, 10.1016/j.cgh.2013.04.028

Salem, 2016, Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology, 151, 1155, 10.1053/j.gastro.2016.08.029

Garlipp, 2014, Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization, Hepatology, 59, 1864, 10.1002/hep.26947

Zucman-Rossi, 2015, Genetic landscape and biomarkers of hepatocellular carcinoma, Gastroenterology, 149, 1226, 10.1053/j.gastro.2015.05.061

Llovet, 2015, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat Rev Clin Oncol, 12, 408, 10.1038/nrclinonc.2015.103

Schulze, 2015, Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, 47, 505, 10.1038/ng.3252

El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 6736, 1

Johnson, 2013, Brivanib vs. sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 31, 3517, 10.1200/JCO.2012.48.4410

Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, et al. Linifanib vs. Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2015;Jan10, 33:172–9.

Cheng, 2013, Sunitinib vs. sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 31, 4067, 10.1200/JCO.2012.45.8372

Zhu, 2015, SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 33, 559, 10.1200/JCO.2013.53.7746

Abou-Alfa, 2010, Doxorubicin plus sorafenib vs. doxorubicin alone in patients with advanced hepatocellular carcinoma, JAMA, 304, 2154, 10.1001/jama.2010.1672

Qin, 2013, Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin vs. doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia, J Clin Oncol, 31, 3501, 10.1200/JCO.2012.44.5643

Llovet, 2013, Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study, J Clin Oncol, 31, 3509, 10.1200/JCO.2012.47.3009

Zhu, 2014, Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial, JAMA, 312, 57, 10.1001/jama.2014.7189

Rimassa L, Assenat E, Peck-Radosavljevic M, Zagonel V, Pracht M, Caremoli ER, et al. Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC). Lancet Oncol. 2018 Apr 3. pii: S1470-2045(18)30146-3. doi: 10.1016/S1470-2045(18)30146-3. [Epub ahead of print].

Llovet, 2014, Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design, Clin Cancer Res, 20, 2072, 10.1158/1078-0432.CCR-13-0547

Abou-Alfa, 2006, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, 4293, 10.1200/JCO.2005.01.3441

Iavarone, 2011, Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy, Hepatology, 54, 2055, 10.1002/hep.24644

Ganten, 2017, Sorafenib in patients with hepatocellular carcinoma—results of the observational INSIGHT study, Clin Cancer Res, 23, 5720, 10.1158/1078-0432.CCR-16-0919

Lencioni, 2014, GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): second interim analysis, Int J Clin Pract, 68, 609, 10.1111/ijcp.12352

Reig, 2013, Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design, Hepatology, 58, 2023, 10.1002/hep.26586

Hollebecque, 2011, Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Aliment Pharmacol Ther, 34, 1193, 10.1111/j.1365-2036.2011.04860.x

Kim, 2011, Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function, Cancer Chemother Pharmacol, 68, 1285, 10.1007/s00280-011-1616-x

Marrero, 2016, Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study, J Hepatol, 65, 1140, 10.1016/j.jhep.2016.07.020

Matsui, 2008, Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase, Clin Cancer Res, 14, 5459, 10.1158/1078-0432.CCR-07-5270

Park, 2011, Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma, Clin Cancer Res, 17, 1973, 10.1158/1078-0432.CCR-10-2011

Spratlin, 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, J Clin Oncol, 28, 780, 10.1200/JCO.2009.23.7537

Villanueva, 2011, Targeted therapies for hepatocellular carcinoma, Gastroenterology, 140, 1410, 10.1053/j.gastro.2011.03.006

Taieb, 2006, Medical treatments for hepatocellular carcinoma (HCC): what’s next?, Ann Oncol, 17, x308, 10.1093/annonc/mdl279

Gish, 2007, Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin, J Clin Oncol, 25, 3069, 10.1200/JCO.2006.08.4046

Yeo, 2005, A randomized phase III study of doxorubicin vs. cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma, J Natl Cancer Inst, 97, 1532, 10.1093/jnci/dji315

Edeline, 2009, Guillygomac’h A, Boudjema K, Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study, World J Gastroenterol, 15, 713, 10.3748/wjg.15.713

Chow, 2002, High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial, Hepatology, 36, 1221, 10.1053/jhep.2002.36824

Barbare, 2005, Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma, J Clin Oncol, 23, 4338, 10.1200/JCO.2005.05.470

Grimaldi, 1998, Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial, J Clin Oncol, 16, 411, 10.1200/JCO.1998.16.2.411

Posey, 2005, Results of a phase 2/3 open-label, randomized trial of T138067 vs. doxorubicin in chemotherapy-naive, unresectable hepatocellular carcinoma, J Clin Oncol, 23, 10.1200/jco.2005.23.16_suppl.4035

Wilhelm, 2011, Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity, Int J Cancer, 129, 245, 10.1002/ijc.25864

Kelley, 2017, Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study, Ann Oncol, 28, 528, 10.1093/annonc/mdw651

Santoro, 2013, Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study, Lancet Oncol, 14, 55, 10.1016/S1470-2045(12)70490-4

Zhu AX, Finn RS, Cattan S, Edeline J, Ogasawara S, Palmer DH, et al. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. J Clin Oncol 2018;36:abstr 2019.

Kumar, 2014, Role of supportive care for terminal stage hepatocellular carcinoma, J Clin Exp Hepatol, 4, S130, 10.1016/j.jceh.2014.03.049

Miaskowski, 2004, Symptom clusters: the new frontier in symptom management research, J Natl Cancer Inst Monogr, 2004, 17, 10.1093/jncimonographs/lgh023

Lin, 2004, Hospice palliative care for patients with hepatocellular carcinoma in Taiwan, Palliat Med, 18, 93, 10.1191/0269216304pm851oa

Rakoski, 2015, Palliative care for patients with end-stage liver disease: An overview, Clin Liver Dis, 6, 19, 10.1002/cld.478

Imani, 2014, The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations, Hepat Mon, 14, e23539, 10.5812/hepatmon.23539

Hamilton J, Runyon B, Bonis P, et al. Management of pain in patients with cirrhosis.uptodateonline.com. http://www.uptodate.com/contents/management-of-pain-in-patients-with-advanced-chronic-liver-disease-or-cirrhosis n.d.

Bosilkovska, 2012, Analgesics in patients with hepatic impairment: pharmacology and clinical implications, Drugs, 72, 1645, 10.2165/11635500-000000000-00000

Smith, 2012, Low absolute bioavailability of oral naloxone in healthy subjects, Int J Clin Pharmacol Ther, 50, 360, 10.5414/CP201646

Guerriero, 2016, Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study, Drug Des Devel Ther, 10, 1515, 10.2147/DDDT.S106025

Madeo, 2015, Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain, J Neurol, 262, 2164, 10.1007/s00415-015-7823-3

Hayashi, 2014, Palliative external-beam radiotherapy for bone metastases from hepatocellular carcinoma, World J Hepatol, 6, 923, 10.4254/wjh.v6.i12.923

Jung, 2017, High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma, Oncotarget, 8, 15182, 10.18632/oncotarget.14858

Hiraoka, 2017, Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib, Hepatol Res, 47, 558, 10.1111/hepr.12780

Pinato, 2012, A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI), Br J Cancer, 106, 1439, 10.1038/bjc.2012.92

Hsu, 2012, Mini-nutritional assessment predicts functional status and quality of life of patients with hepatocellular carcinoma in Taiwan, Nutr Cancer, 64, 543, 10.1080/01635581.2012.675620

Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology n.d.; 10:19–28.

Maguire, 1999, Improving communication with cancer patients, Eur J Cancer, 35, 2058, 10.1016/S0959-8049(99)00301-9

Fallowfield, 1998, Teaching senior oncologists communication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom, J Clin Oncol, 16, 1961, 10.1200/JCO.1998.16.5.1961

Tapper, 2015, Psychoactive medications increase the risk of falls and fall-related injuries in hospitalized patients with cirrhosis, Clin Gastroenterol Hepatol, 13, 1670, 10.1016/j.cgh.2015.03.019

WHO definition of palliative care. Geneva, World Health Organization, 2010 (http://www.who.int/cancer/palliative/ definition/en, accessed 18 June 2017) n.d.

Levy, 2009, NCCN clinical practice guidelines in oncology: palliative care, J Natl Compr Canc Netw, 7, 436, 10.6004/jnccn.2009.0031

Hamano, 2015, Surprise questions for survival prediction in patients with advanced cancer: a multicenter prospective cohort study, Oncologist, 20, 839, 10.1634/theoncologist.2015-0015

Hwang, 2013, Hospice offers more palliative care but costs less than usual care for terminal geriatric hepatocellular carcinoma patients: a nationwide study, J Palliat Med, 16, 780, 10.1089/jpm.2012.0482

Oppong Y, Navarro VJ, Reville B, Sohal PKB, Parks S. Palliative Care for Hepatocellular Carcinoma Patients. Gastroenterology 2011;140:S-925.

Clements A, Greenslade L. Nursing care for end-stage liver disease. Nurs Times n.d.; 110:16–9.

Fleming, 2005, Surrogate endpoints and FDA’s accelerated approval process, Health Aff, 24, 67, 10.1377/hlthaff.24.1.67

Lee, 2016, TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials, Br J Cancer, 115, 1201, 10.1038/bjc.2016.322

Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M, Barbara M, et al. Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology 2015;Sep;62:784–91.

Okita, 2015, Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study, J Gastroenterol, 50, 191, 10.1007/s00535-014-0956-9

Lencioni, 2013, New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma, Clin Cancer Res, 19, 1312, 10.1158/1078-0432.CCR-12-3796

Fiteni, 2014, Endpoints in cancer clinical trials, J Visc Surg, 151, 17, 10.1016/j.jviscsurg.2013.10.001

Vouche, 2014, Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy, Hepatology, 60, 192, 10.1002/hep.27057

Seyal, 2015, Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma, Hepatology, 62, 1111, 10.1002/hep.27915

Bargellini, 2013, Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants, Eur J Radiol, 82, e212, 10.1016/j.ejrad.2012.12.009

Vincenzi, 2015, Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis, PLoS One, 10, e0133488, 10.1371/journal.pone.0133488

Lencioni, 2017, Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC, J Hepatol, 66, 1166, 10.1016/j.jhep.2017.01.012

Meyer, 2017, MRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs. sorafenib, Liver Int, 37, 1047, 10.1111/liv.13359